Approval · Notice of Compliance 18744 · 2016
EXJADE: Notice of Compliance 18744
Issued December 2, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18744
- Date
- December 2, 2016
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Fulfillment of the post-approval commitments for the notice of compliance with conditions for management of chronic iron overload in patients with transfusion-dependent anemias
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EXJADE | Not yet assigned | — |
Medicinal ingredients
- DEFERASIROX 125 MG per TAB
- DEFERASIROX 250 MG per TAB
- DEFERASIROX 500 MG per TAB